Table 5: Comparison of SVR and non-SVR patients treated with peginterferon, ribavirin, and telaprevir by univariate analysis (a) and multivariate analysis (b).
(a) Univariate analysis

SVR, Non-SVR, values (SVR versus non-SVR groups)

Gender, male/female24/85/20.77
Age, years57.8 ± 9.359.8 ± 5.60.58
Previous treatment: naïve/relapse/null14/17/13/2/20.13
AST, IU/L55.9 ± 50.144.7 ± 16.00.56
ALT, IU/L71.9 ± 70.651.1 ± 19.90.44
γ-GTP, IU/L62.1 ± 64.746.2 ± 27.90.53
Hemoglobin, g/dL14.6 ± 1.314.4 ± 1.60.72
Platelets, ×104/mm316.4 ± 5.214.3 ± 4.60.33
HCV RNA ()6.45 ± 0.686.81 ± 0.750.220
Treatment response
 RVR, 270<0.0001
 EVR, 322<0.0001
 IFNL4, major/minor/ND22/8/22/5/00.0727

Null: null response; AST: aspirate aminotransferase; ALT: alanine aminotransferase; γ-GTP: γ-glutamyltransferase; RVR: rapid virological response; EVR: early virological response; SVR: sustained virological response.
(b) Factors associated with SVR among patients treated with peginterferon, ribavirin, and telaprevir by multivariate analysis

FactorCategoryOdds ratio95% CI values

HCV RNA (log IU/mL)<6.4/6.4≤13.741.014–186.300.048
IFNL4
ss469415590
major/minor17.541.980–156.250.010